Orchard Therapeutics
Treating rare disorders through innovative gene therapies.
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 6765 % | (91 %) | 21 % | 3 % | (81 %) | 1346 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (6667 %) | (169 %) | (11264 %) | (6531 %) | (5718 %) | (7358 %) | (116 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 6667 % | (175 %) | (11103 %) | (6503 %) | (5857 %) | (7526 %) | (113 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 144 % | 9890 % | 4670 % | 3612 % | 4834 % | 366 % |
Source: Company filings or news article
Related Content
Orchard Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically in the field of gene therapy. The company's primary focus is on developing and commercializing innovative gene therapies for patients with severe genetic diseases. Orchard's business model revolves around the application of its Hematopoietic Stem Cell (HSC) gene therapy platform, which is designed to replace a patient's faulty genes with healthy ones. This is achieved by modifying the patient's own stem cells outside the body and then reintroducing them, potentially offering a one-time, curative treatment for various genetic diseases.
The company's target market includes patients suffering from severe genetic diseases, a segment with significant medical need and limited therapeutic options. Orchard's potential clients are therefore individuals, families, and healthcare providers seeking effective treatments for these conditions.
Orchard generates revenue by developing and commercializing its gene therapies. Once a therapy is approved for use, the company can sell it to healthcare providers or directly to patients. The company is also likely to earn income from partnerships with other biotech and pharmaceutical companies, research grants, and potentially, royalties from licensed technologies.
The company's CEO, Bobby Gaspar, emphasizes the team's passion and commitment to transforming the lives of patients with severe genetic diseases. As of 2022, Orchard is looking forward to reaching new milestones and exploring new opportunities in the gene therapy space.
Keywords: Biotechnology, Healthcare, Gene Therapy, Genetic Diseases, Hematopoietic Stem Cell (HSC), Therapeutic Platform, Medical Need, Revenue Generation, Partnerships, Patient-Centric.